Meghan Sara Drastal, Sarah de Ferranti, Holly Gooding
{"title":"Recent updates on the screening, diagnosis, and management of lipids disorders in children and adolescents.","authors":"Meghan Sara Drastal, Sarah de Ferranti, Holly Gooding","doi":"10.1097/MOP.0000000000001460","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>The purpose of this review is to provide an update on screening, diagnosis, and treatment of lipid disorders in the pediatric patient.</p><p><strong>Recent findings: </strong>Apart from the United States Preventive Services Task Force (USPSTF), the majority of medical societies recommend universal screening for lipid disorders in children and adolescents 21 years or younger. Recent population studies confirm lipid abnormalities are prevalent in children, affecting at least one in five children aged 6-19 years. A systematic review and network meta-analysis of lipid-lowering therapies in children and adolescents with familial hypercholesterolemia found that statins reduced LDL-C by 33.61% and adding ezetimibe reduced LDL-C by an additional 15.85%.</p><p><strong>Summary: </strong>Nearly all major medical societies recommend universal lipid screening in children aged 9-11 and 17-21. Lipid abnormalities are common, and diagnosis is generally made by confirming abnormal lipid results with fasting lipid studies. Lifestyle modifications and statins are the mainstay for treatment of dyslipidemia. However, most research on lipid-lowering therapies is in familial hypercholesterolemia.</p>","PeriodicalId":10985,"journal":{"name":"Current opinion in pediatrics","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current opinion in pediatrics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MOP.0000000000001460","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose of review: The purpose of this review is to provide an update on screening, diagnosis, and treatment of lipid disorders in the pediatric patient.
Recent findings: Apart from the United States Preventive Services Task Force (USPSTF), the majority of medical societies recommend universal screening for lipid disorders in children and adolescents 21 years or younger. Recent population studies confirm lipid abnormalities are prevalent in children, affecting at least one in five children aged 6-19 years. A systematic review and network meta-analysis of lipid-lowering therapies in children and adolescents with familial hypercholesterolemia found that statins reduced LDL-C by 33.61% and adding ezetimibe reduced LDL-C by an additional 15.85%.
Summary: Nearly all major medical societies recommend universal lipid screening in children aged 9-11 and 17-21. Lipid abnormalities are common, and diagnosis is generally made by confirming abnormal lipid results with fasting lipid studies. Lifestyle modifications and statins are the mainstay for treatment of dyslipidemia. However, most research on lipid-lowering therapies is in familial hypercholesterolemia.
期刊介绍:
Current Opinion in Pediatrics is a reader-friendly resource which allows the reader to keep up-to-date with the most important advances in the pediatric field. Each issue of Current Opinion in Pediatrics contains three main sections delivering a diverse and comprehensive cover of all key issues related to pediatrics; including genetics, therapeutics and toxicology, adolescent medicine, neonatology and perinatology, and orthopedics. Unique to Current Opinion in Pediatrics is the office pediatrics section which appears in every issue and covers popular topics such as fever, immunization and ADHD. Current Opinion in Pediatrics is an indispensable journal for the busy clinician, researcher or student.